IQWiG says Zaltrap has 'marginal' benefit for mCRC

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that Zaltrap aflibercept (Zaltrap ziv-aflibercept-U.S.) from Sanofi (Euronext:SAN; NYSE:SNY) has "marginal" additional benefit to treat metastatic colorectal cancer (mCRC) vs. FOLFIRI chemotherapy, the comparator requested by Germany's Federal Joint Committee (G-BA). IQWiG said Zaltrap significantly improved overall survival (OS) over the comparator but also led to more serious and severe adverse events in the Phase III VELOUR trial. Comments on the assessment are due June 24; a final assessment from G-BA is expected in mid-August. ...